Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 201

1.

BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study.

Hutterer GC, Posch F, Buser L, Zigeuner R, Morshäuser L, Otto W, Wild PJ, Burger M, May M, Pichler M, Brookman-May SD.

Urol Oncol. 2019 May 3. pii: S1078-1439(19)30137-1. doi: 10.1016/j.urolonc.2019.04.004. [Epub ahead of print]

PMID:
31060796
2.

Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis.

Moik F, Riedl JM, Winder T, Terbuch A, Rossmann CH, Szkandera J, Bauernhofer T, Kasparek AK, Schaberl-Moser R, Reicher A, Prinz F, Pichler M, Stöger H, Stotz M, Gerger A, Posch F.

Sci Rep. 2019 Apr 3;9(1):5548. doi: 10.1038/s41598-019-42069-1.

3.

Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?

Pichler R, Compérat E, Klatte T, Pichler M, Loidl W, Lusuardi L, Schmidinger M.

Cancers (Basel). 2019 Mar 25;11(3). pii: E422. doi: 10.3390/cancers11030422.

4.

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G.

J Clin Oncol. 2019 Mar 15:JCO1801480. doi: 10.1200/JCO.18.01480. [Epub ahead of print]

PMID:
30875280
5.

Hedgehog pathway proteins SMO and GLI expression as prognostic marker in head and neck squamous cell carcinoma - a retrospective immunohistochemical study.

Richtig G, Aigelsreiter AM, Asslaber M, Weiland T, Pichler M, Eberhard K, Sygulla S, Schauer S, Hoefler G, Aigelsreiter A.

Histopathology. 2019 Mar 12. doi: 10.1111/his.13860. [Epub ahead of print]

PMID:
30861166
6.
7.

The Implications of the Long Non-Coding RNA NEAT1 in Non-Cancerous Diseases.

Prinz F, Kapeller A, Pichler M, Klec C.

Int J Mol Sci. 2019 Feb 1;20(3). pii: E627. doi: 10.3390/ijms20030627. Review.

8.

MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.

Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, Stanzer S, Rinnerthaler G, Stoeger H, Bauernhofer T, Haybaeck J, Hoefler G, Jahn SW, Parrella P, Calin GA, Pichler M.

Breast Cancer Res. 2019 Feb 1;21(1):20. doi: 10.1186/s13058-019-1104-5.

9.

High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer.

Pichler R, Loidl W, Pichler M.

Transl Androl Urol. 2018 Dec;7(Suppl 6):S738-S740. doi: 10.21037/tau.2018.08.15. No abstract available.

10.

Involvement of long non-coding RNA HULC (highly up-regulated in liver cancer) in pathogenesis and implications for therapeutic intervention.

Klec C, Gutschner T, Panzitt K, Pichler M.

Expert Opin Ther Targets. 2019 Mar;23(3):177-186. doi: 10.1080/14728222.2019.1570499. Epub 2019 Jan 24.

PMID:
30678498
11.

Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer-the more specific, the better?

Smolle E, Pichler M.

J Thorac Dis. 2018 Nov;10(Suppl 33):S3961-S3964. doi: 10.21037/jtd.2018.09.81. No abstract available.

12.

Involvement of the long noncoding RNA NEAT1 in carcinogenesis.

Klec C, Prinz F, Pichler M.

Mol Oncol. 2019 Jan;13(1):46-60. doi: 10.1002/1878-0261.12404. Epub 2018 Dec 3. Review.

13.

Long non-coding RNA CCAT2 as a therapeutic target in colorectal cancer.

Foßelteder J, Calin GA, Pichler M.

Expert Opin Ther Targets. 2018 Dec;22(12):973-976. doi: 10.1080/14728222.2018.1541453. Epub 2018 Oct 30. No abstract available.

PMID:
30365347
14.

MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.

Terbuch A, Adiprasito JB, Stiegelbauer V, Seles M, Klec C, Pichler GP, Resel M, Posch F, Lembeck AL, Stöger H, Szkandera J, Pummer K, Bauernhofer T, Hutterer GC, Gerger A, Stotz M, Pichler M.

Int J Mol Sci. 2018 Oct 12;19(10). pii: E3130. doi: 10.3390/ijms19103130.

15.

Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer.

Lembeck AL, Posch F, Klocker EV, Szkandera J, Schlick K, Stojakovic T, Kornprat P, Lackner C, Gerger A, Stoeger H, Stotz M, Pichler M.

Clin Chem Lab Med. 2019 Apr 24;57(5):740-744. doi: 10.1515/cclm-2018-0016.

PMID:
30307891
16.

Continuous, label-free, 96-well-based determination of cell migration using confluence measurement.

Mayr C, Beyreis M, Dobias H, Gaisberger M, Fuchs J, Pichler M, Ritter M, Jakab M, Helm K, Neureiter D, Kiesslich T.

Cell Adh Migr. 2019 Dec;13(1):76-82. doi: 10.1080/19336918.2018.1526612. Epub 2018 Oct 8.

PMID:
30295122
17.

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.

Richtig G, Hoeller C, Wolf M, Wolf I, Rainer BM, Schulter G, Richtig M, Grübler MR, Gappmayer A, Haidn T, Kofler J, Huegel R, Lange-Asschenfeldt B, Pichler M, Pilz S, Heinemann A, Richtig E.

PLoS One. 2018 Oct 1;13(10):e0204729. doi: 10.1371/journal.pone.0204729. eCollection 2018.

18.

Cytoplasmic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival.

Fechter K, Feichtinger J, Prochazka K, Unterluggauer JJ, Pansy K, Steinbauer E, Pichler M, Haybaeck J, Prokesch A, Greinix HT, Beham-Schmid C, Neumeister P, Thallinger GG, Deutsch AJA.

Sci Rep. 2018 Sep 28;8(1):14528. doi: 10.1038/s41598-018-32972-4.

19.

Early Loss of Forkhead Transcription Factor, O Subgroup, Member 1 Protein in the Development of Pancreatic Ductal Adenocarcinoma.

Al-Zoughbi W, Schauer S, Pichler M, Hoefler G.

Pathobiology. 2018;85(5-6):342-347. doi: 10.1159/000492433. Epub 2018 Sep 18.

20.

Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling.

Shen P, Reineke LC, Knutsen E, Chen M, Pichler M, Ling H, Calin GA.

Mol Oncol. 2018 Nov;12(11):1856-1870. doi: 10.1002/1878-0261.12384. Epub 2018 Oct 15.

Supplemental Content

Loading ...
Support Center